[go: up one dir, main page]

ES2141929T3 - Produccion y aislamiento muy eficientes de particulas viricas. - Google Patents

Produccion y aislamiento muy eficientes de particulas viricas.

Info

Publication number
ES2141929T3
ES2141929T3 ES95914170T ES95914170T ES2141929T3 ES 2141929 T3 ES2141929 T3 ES 2141929T3 ES 95914170 T ES95914170 T ES 95914170T ES 95914170 T ES95914170 T ES 95914170T ES 2141929 T3 ES2141929 T3 ES 2141929T3
Authority
ES
Spain
Prior art keywords
exchange resin
cells
viral particles
isolation
retroviral particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95914170T
Other languages
English (en)
Inventor
Christopher P Prior
David M Weber
Richard S Gore
James J Harter
Michael E Hrinda
Jonathan J Mitschelen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immune Response Corp
Original Assignee
Immune Response Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Response Corp filed Critical Immune Response Corp
Application granted granted Critical
Publication of ES2141929T3 publication Critical patent/ES2141929T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

ESTA INVENCION SE REFIERE A UN PROCESO CONTINUO PARA PRODUCIR PARTICULAS VIRALES QUE COMPRENDE PROPORCIONAR EN UN MEDIO DE CRECIMIENTO PERFUSIONADO UNA POBLACION DE CELULAS NO LITICAS INFECTADAS VIRALMENTE Y ELIMINAR EL MEDIO QUE CONTIENE DICHAS CELULAS EN UN INDICE QUE MANTENGA UN CRECIMIENTO CON UNA FASE DE PERFIL DE REGIMEN PERMANENTE DE LAS CELULAS QUE PERMANEZCAN EN DICHO MEDIO DE CRECIMIENTO PERFUSIONADO. LA INVENCION ESTA TAMBIEN DIRIGIDA A UN PROCESO PARA PURIFICAR PARTICULAS RETROVIRALES QUE COMPRENDE PASAR UNA SOLUCION QUE CONTIENE LAS PARTICULAS RETROVIRALES Y CONTAMINANTES A TRAVES DE UNA RESINA, DE INTERCAMBIO DE IONES Y ELUIR LAS PARTICULAS RETROVIRALES DE LA RESINA.
ES95914170T 1994-03-22 1995-03-22 Produccion y aislamiento muy eficientes de particulas viricas. Expired - Lifetime ES2141929T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21583394A 1994-03-22 1994-03-22

Publications (1)

Publication Number Publication Date
ES2141929T3 true ES2141929T3 (es) 2000-04-01

Family

ID=22804586

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95914170T Expired - Lifetime ES2141929T3 (es) 1994-03-22 1995-03-22 Produccion y aislamiento muy eficientes de particulas viricas.

Country Status (12)

Country Link
US (2) US5661023A (es)
EP (1) EP0751988B1 (es)
JP (1) JP3313117B2 (es)
AT (1) ATE189697T1 (es)
AU (1) AU2127395A (es)
CA (1) CA2186034C (es)
DE (1) DE69515028T2 (es)
DK (1) DK0751988T3 (es)
ES (1) ES2141929T3 (es)
GR (1) GR3033268T3 (es)
PT (1) PT751988E (es)
WO (1) WO1995025789A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2127395A (en) * 1994-03-22 1995-10-09 Rhone-Poulenc Rorer Pharmaceuticals Inc. Highly efficient production and isolation of viral particles
AU3447097A (en) * 1996-07-01 1998-01-21 Rhone-Poulenc Rorer S.A. Method for producing recombinant adenovirus
FR2750433B1 (fr) * 1996-07-01 1998-08-14 Rhone Poulenc Rorer Sa Procede de production d'adenovirus recombinants
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
CA2272820C (en) 1996-11-20 2012-09-11 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
PT1944362E (pt) * 1997-09-05 2016-01-27 Genzyme Corp Métodos de produção de preparações de alto título de vetores aav recombinantes desprovidos de adjuvantes
JP2002500088A (ja) * 1998-01-12 2002-01-08 ハー マジェスティ イン ライト オブ カナダ アズ リプレゼンティッド バイ ザ ミニスター オブ アグリカルチャー アンド アグリ−フード カナダ 非極性抽出物の単離、回収及び精製方法
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
DE10010342A1 (de) * 2000-03-06 2001-09-20 Merck Patent Gmbh Verfahren zur Abreicherung von Endotoxinen
SE0001132D0 (sv) * 2000-03-29 2000-03-29 Cavidi Tech Ab Method of concentrating and recovering a viral enzyme activity from biological samples
US20040101964A1 (en) * 2000-05-10 2004-05-27 Shigemitsu Takashima Method of preparing virus vector
WO2002044394A2 (en) 2000-11-29 2002-06-06 University Of Southern California Targetet retoviral vectors for cancer immunotherapy
MXPA03007141A (es) * 2001-02-11 2003-11-18 Aquanova Ger Solubilisate Tech Procedimiento para la preparacion de un concentrado de ingredientes activos, y un concentrado de ingredientes activos.
US20030031626A1 (en) * 2001-07-26 2003-02-13 Thomas Rheinlander Process for the production of pharmaceutical preparations
DE10137515A1 (de) * 2001-07-26 2003-02-13 Diagnostikforschung Inst Verfahren zur Herstellung pharmazeutischer Zubereitungen
US8052966B2 (en) 2003-04-21 2011-11-08 University Of Southern California Methods and compositions for treating metastatic cancer
US20090123428A1 (en) * 2003-04-21 2009-05-14 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
US20070178066A1 (en) * 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
KR20070104339A (ko) 2004-11-03 2007-10-25 인트로겐 테라페티스, 인코퍼레이티드 아데노바이러스 벡터의 생산과 정제를 위한 신규한 방법
PL2307551T3 (pl) 2008-06-18 2017-07-31 Oxford Biomedica (Uk) Limited Oczyszczanie wektorów retrowirusowych
JP2013523175A (ja) 2010-04-14 2013-06-17 イーエムディー・ミリポア・コーポレーション 高力価、高純度のウイルスストックの作製方法及びその使用方法
DE102010046817A1 (de) * 2010-09-28 2012-03-29 Sartorius Stedim Biotech Gmbh Verfahren zur Abtrennung von Viren aus einem Kontaminanten enthaltenden flüssigen Medium
EP2700399B1 (en) 2011-04-18 2017-05-31 National Center of Neurology and Psychiatry Drug delivery particles and method for producing same
MY195756A (en) 2012-09-17 2023-02-09 Grace W R & Co Functionalized Particulate Support Material and Methods of Making and Using the Same
PL2812091T3 (pl) 2012-09-17 2021-07-19 W.R. Grace & Co. - Conn. Podłoża chromatograficzne i urządzenia
EP3094390B1 (en) 2014-01-16 2021-07-07 W.R. Grace & CO. - CONN. Affinity chromatography media and chromatography devices
JP6914189B2 (ja) 2014-05-02 2021-08-04 ダブリュー・アール・グレース・アンド・カンパニー−コーンＷ Ｒ Ｇｒａｃｅ ＆ Ｃｏ−Ｃｏｎｎ 官能化担体材料並びに官能化担体材料を作製及び使用する方法
CN107921407B (zh) 2015-06-05 2022-07-05 格雷斯公司 生物处理吸附澄清剂及其制备和使用方法
EP3714033A1 (en) * 2017-11-22 2020-09-30 Corning Incorporated Perfusion bioreactor system and perfusion cell culture method
US11028124B2 (en) 2018-05-07 2021-06-08 Repligen Corporation Methods, devices and systems for 3-stage filtration
US20220243224A1 (en) * 2019-04-15 2022-08-04 Children's Hospital Medical Center Viral vector manufacturing methods

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3509070A (en) * 1968-06-13 1970-04-28 American Home Prod Adsorbent for chromatographic purification of virus
US3655509A (en) * 1969-05-29 1972-04-11 Monsanto Co Process for the separation of virus from non-viral proteins
US3925152A (en) * 1971-06-18 1975-12-09 Exploaterings Ab Tbf Virus separation
US4647773A (en) * 1984-04-23 1987-03-03 The United States Of America As Represented By The Department Of Health And Human Services Method of continuous production of retroviruses (HTLV-III) from patients with AIDS and pre-AIDS
JPS6147185A (ja) * 1984-08-09 1986-03-07 Chemo Sero Therapeut Res Inst 日本脳炎ウイルスの精製方法
JPS6151571A (ja) * 1984-08-21 1986-03-14 Nippon Seibutsu Kagaku Kenkyusho オ−エスキ−病診断用抗原の単離・精製法
UA27716C2 (uk) * 1987-06-10 2000-10-16 Дзе Імюн Респонс Корпорейшн Інк. Імуноген для лікування індивідуума, зараженого ретровірусом віл
NZ225583A (en) * 1987-08-06 1991-07-26 Merck & Co Inc Process for purifying hepatitis a virions (hav)
WO1991013906A1 (en) * 1990-03-09 1991-09-19 Chiron Corporation PURIFIED gp120 COMPOSITION RETAINING NATURAL CONFORMATION
FR2661834B1 (fr) * 1990-05-09 1995-01-27 Merieux Inst Procede de fabrication d'immunogenes de retrovirus et de vaccins contre les infections retrovirales, notamment hiv, et immunogenes et vaccins obtenus.
CA2098510A1 (en) * 1990-12-13 1992-06-14 Kenneth W. Culver Sustained and continuous production of high titers of recombinant viral vectors and transduced target cells for use in gene therapy
AU2127395A (en) * 1994-03-22 1995-10-09 Rhone-Poulenc Rorer Pharmaceuticals Inc. Highly efficient production and isolation of viral particles
JPH08195877A (ja) * 1995-01-18 1996-07-30 Canon Inc イメージセンサと画像処理回路

Also Published As

Publication number Publication date
US5661023A (en) 1997-08-26
ATE189697T1 (de) 2000-02-15
JPH10500286A (ja) 1998-01-13
EP0751988B1 (en) 2000-02-09
US6080571A (en) 2000-06-27
EP0751988A4 (en) 1997-11-12
JP3313117B2 (ja) 2002-08-12
AU2127395A (en) 1995-10-09
CA2186034A1 (en) 1995-09-28
WO1995025789A1 (en) 1995-09-28
DE69515028D1 (de) 2000-03-16
DE69515028T2 (de) 2000-06-29
PT751988E (pt) 2000-05-31
DK0751988T3 (da) 2000-06-26
CA2186034C (en) 2002-11-26
EP0751988A1 (en) 1997-01-08
GR3033268T3 (en) 2000-09-29

Similar Documents

Publication Publication Date Title
ES2141929T3 (es) Produccion y aislamiento muy eficientes de particulas viricas.
EP1394259A3 (en) Recombinant infectious non-segmented negative strand RNA virus
HUP0001271A1 (hu) Eljárás rekombináns adenovírusok előállítására
DE69634904D1 (de) Negativstrand rna virus mit selbständiger replikationsaktivität
DK0923592T3 (da) Fremgangsmåder til rensning af nukleinsyrer
MX9701183A (es) Procedimiento de preparacion del virus gripal, antigenos obtenidos y sus aplicaciones.
DE69835294D1 (de) Methode zur in vitro auseinander- und wiederzusammensetzung von papillomavirus virus-ähnlichen tielchen (vlps)
FR2465508B1 (fr) Membranes poreuses contenant du polyacrylonitrile modifie, pour l'ultrafiltration, procede de preparation de celles-ci et applications desdites membranes
TR199901840T2 (xx) DNA'nın cross-flow-filtrasyonu ile temizlenmesi.
FR2756297B1 (fr) Procede de production de virus recombinants
PT88178A (pt) Metodo para a purificacao de virus da hepatite a
NO931093D0 (no) Fremgangsmaate for fremstilling av rensede glykolipider ved membrana dskillelsesfremgangsmaaten
FR2658092B1 (fr) Procede de purification de solutions de polyorganophosphazene par membranes.
NO983834L (no) En fremgangsmÕte ved rensingen av opasifiserende kontrastmidler
DK1103618T3 (da) Fremgangsmåde til oprensning af 1,3-propandiol fra fermenteringsmedie
FR2600341B1 (fr) Procede de purification d'un produit d'expression genetique obtenu par technique d'adn recombinant
ES2193210T3 (es) Separacion de virus de soluciones de proteinas por ultrafiltracion.
ES8608581A1 (es) Un metodo para la construccion de un gen sintetico para pro-teina objetivo viral
PT1071744E (pt) Filtracao por membrana
DE69324645D1 (de) Verfahren zur Herstellung von Hepatitis Antigenen und Impfstoffen
ATE133709T1 (de) Peroxidase-gen von mikrobischem ursprung
DK78990A (da) Fremgangsmaade til rensning af ydre membran protein for haemophilus influenza
DE69103798D1 (de) Katalysatorsystem und -verfahren zur selektiven Herstellung von Isoprenyl-Alkylethern aus Isopren.
FR2509630B1 (fr) Procede pour eliminer des impuretes, notamment le potassium, des catalyseurs usages d'argent pour la production d'oxyde d'ethylene
SE9303645D0 (sv) Sätt att rena avloppsvatten

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 751988

Country of ref document: ES